Cytokine News and Research

RSS

UC Davis launches two clinical trials to evaluate treatments for COVID-19

UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.

27 Mar 2020

Model that sheds light on severe Duchenne muscular dystrophy could pave the way for new therapies

Researchers have developed an experimental model of severe Duchenne muscular dystrophy that offers insight into the disease.

26 Mar 2020

Combination produces more proliferative, enduring central memory T cells for cellular therapy

Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs them into a stronger T cell type that persists longer than its comrades, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Immunology Research, a journal of the American Association for Cancer Research.

25 Mar 2020

New understanding of signaling molecule interleukin-2 can guide drug discovery efforts

The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.

17 Mar 2020

What does COVID-19 do to the body?

The novel coronavirus SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19, and that is spreading throughout the world is causing panic in almost all countries. With a death rate ranging from 1% to 2% in young patients but about 5%-8% in elderly and sick patients, it is capable of ravaging multiple organ systems in the human body.

12 Mar 2020

Research shows how immune cells act to limit tumor development

How does the immune system act to limit tumor development? Using in vivo imaging tools, scientists from the Institut Pasteur and Inserm described the spatiotemporal activity of tumor-infiltrating T lymphocytes, both locally and remotely.

12 Mar 2020

Researchers find link between interferon, neuroinflammation and synapse loss in Alzheimer's

When immunologist Dr. Wei Cao joined Baylor College of Medicine three-and-a-half years ago, her first project was to investigate how inflammation contributes to Alzheimer's disease.

5 Mar 2020

Social isolation could be linked to increased inflammation in the body

Social isolation could be associated with increased inflammation in the body new research from the University of Surrey and Brunel University London has found.

5 Mar 2020

Scientists find link between immune system and high blood pressure in patients with CKD

Detecting threats, sending out response molecules, and altering gene expression--our immune system works tirelessly day and night to protect us from invading pathogens and maintain general health and wellbeing.

3 Mar 2020

Boehringer Ingelheim and Trutino enter into research collaboration to advance cytokine therapies

Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine platform.

From Boehringer Ingelheim International GmbH 28 Feb 2020

Omega-3 fatty acids may help prevent complications in women receiving breast implants

For women receiving breast implants during reconstructive or cosmetic breast surgery, scarring around the implant - called capsular contracture - is a common, costly, and painful complication.

26 Feb 2020

Targeted combinatorial drug treatment restores beta cell function in mice

The loss of the identity of insulin-secreting beta cells in the islet of Langerhans, a process also called beta cell dedifferentiation, has been proposed to be a main reason for the development of diabetes.

20 Feb 2020

Study gives clues on how to stop HIV reemergence

A new study released today in the Journal of Virology gives insights into how the HIV-1 virus, which often persists in the body despite antiretroviral treatment, reemerges when treatment stops. More importantly, the study also gives clues on how to stop this reemergence from occurring.

12 Feb 2020

Researchers engineer probiotics to safely deliver immunotherapies to tumors

Researchers at Columbia Engineering have engineered probiotics to safely deliver immunotherapies within tumors.

12 Feb 2020

CD19 CAR NK cell therapy clinical trial shows encouraging results for hematologic cancers

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia, with no major toxicities observed.

6 Feb 2020

Age-linked cognitive decline could be slowed by immune activation

A new study published in February 2020 in the Journal of Experimental Medicine (JEM), reports that activating a specific type of immune cell found in the brain could delay reduced cognition often found in older people, and even prevent neurologic degeneration of age.

5 Feb 2020

Flickering light triggers the brain to release signaling chemicals that may help fight Alzheimer's

For over a century, Alzheimer's disease has confounded all attempts to treat it. But in recent years, perplexing experiments using flickering light have shown promise.

4 Feb 2020

Ludwig Cancer Research study develops a safer CAR-T therapy

A Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell-;a family of promising immunotherapies for cancer- that can be switched on and off on demand.

3 Feb 2020

FDA gives clearance to IND application for Calibr's 'switchable' CAR-T cell therapy

Calibr, the drug discovery and development division of Scripps Research, today announced that the U.S. Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's "switchable" CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.